Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Dermatologists Shed Light On Common Pigmentation Problems And Solutions In Skin Of Color
As we age, brown spots and splotchy skin are all too often a fact of life. But for people with darker skin, changes in pigmentation can occur without warning at any age and can be very difficult to treat. Fortunately, dermatologists can help people with skin of color diagnose and treat bothersome pigmentation problems.
generic viagra online
Bone From Blood: Circulating Cells Form Bone Outside The Normal Skeleton
The accepted dogma has been that bone-forming cells, derived from the body"s connective tissue, are the only cells able to form the skeleton. However, new research shows that specialized cells in the blood share a common origin with white blood cells derived from the bone marrow and that these bloodstream cells are capable of forming bone at sites distant from the original skeleton. This work, published online this month in the journal Stem Cells, represents the first example of how circulating cells may contribute to abnormal bone formation.
News of the day
Varian's RapidArc Radiotherapy Technology Enables Pioneering Cancer Treatments At Top Dutch Oncology Center
Doctors in the Netherlands have developed new ways to perform radiosurgery on benign acoustic tumors using fast and precise RapidArc(TM) radiotherapy technology from Varian Medical Systems (NYSE: VAR). This is among the findings in several papers published by the team at VU University Medical Center in Amsterdam.
Health Insurance

New Treatment Option In The Fight Against Prostate Cancer - Implant Gives Men Flexibility In Treatment Choices

A new 12 month hormone therapy treatment is launched for men with advanced prostate cancer. The Vantas® (histrelin) implant is a small and flexible device, made from the same materials as soft contact lenses. Vantas® is the first 12 month implant to treat prostate cancer to be available in the UK.1 The Vantas® implant is unique in that it is placed under the skin in the upper arm and releases luteinising hormone-releasing hormone (LHRH) over a continuous 12 month period, and is an alternative treatment option to other available LHRH therapies which are currently available as treatments given every one or three months.1,2 The aim is to provide a convenient option for men who wish to continue with their lives as normally as possible with minimum disruption caused by their prostate cancer treatment. Mr John Anderson, Consultant Urologist at Royal Hallamshire Hospital, Sheffield said: "Vantas® represents a milestone in terms of opening up treatment choice for men with advanced prostate cancer - that is metastatic, late stage and locally advanced types of the disease. Metastatic cancer accounts for 20 - 30% of men diagnosed with prostate cancer.3 The Vantas® implant is simple and quick to insert2 and means these men can continue to live life, work and travel without the need for more regular injections - although it is of course still important that they keep to scheduled check-up appointments." Mr Anderson continued: "Vantas® is also unique in that the implant can be quickly removed, which is important if side effects need to be quickly stopped.2 The side effects of LHRH hormone therapies such as Vantas® include hot flushes, impotence or decreased libido.1" Rebecca Porta of the male cancer charity Orchid said, "Around 35,000 men are diagnosed with prostate cancer in the UK each year4 and over 10,000 will die from it.5 We welcome new treatment options that doctors can discuss with patients and their families, especially those which can offer patients an improved quality of life." Most men with advanced prostate cancer are recommended to have hormonal therapy6 and one of the options recommended by the National Institute for Health and Clinical Excellence is the use of LHRH agonists7, synthetic versions of the normal hormone released by humans. Vantas® is a LHRH agonist which means it inhibits the production of testosterone in the body, therefore slowing the growth of prostate cancer cells. References 1- Vantas Summary of Product Characteristics, October 2007 2- Crawford DC, A review of the use of histrelin in the treatment of prostate cancer, manuscript 2008 3- http://www.cancerhelp.org.uk/help/default.asp?page=3505 (last accessed June 2009) 4- htthttp://www.prostatecancermatters.org.uk/faq.asp (last accessed June 2009) 5- http://info.cancerresearchuk.org/cancerstats/types/prostate/ (last accessed June 2009) 6- Click here (last accessed June 2009) 7- National Institute for Health and Clinical Excellence, Prostate Cancer - Diagnosis and treatment. February 2008 http://www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf Orion


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009